肝硬化急性肾损伤EASL管理算法的前瞻性验证
本研究在连续住院的肝硬化急性肾损伤(AKI)患者中前瞻性验证EASL管理算法,共纳入139例患者的202次AKI发作。总体治疗应答率为80%,仅8%需要肾脏替代治疗;符合肝肾综合征(HRS-AKI)诊断标准者30例,对特利加压素应答率为61%;3例使用特利加压素者发生肺水肿。
要点
- EASL算法应用于肝硬化AKI总应答率80%,仅8%需肾脏替代治疗。
- 不符合HRS-AKI诊断标准者应答率70%,急性肾小管坏死为最常见表型。
- 符合HRS-AKI者30例,对特利加压素应答率61%,3例发生肺水肿。
核心结论
- 应用EASL AKI算法与很高的应答率相关,且未显著延迟特利加压素治疗的启动。
- 这些发现支持该算法在临床实践中使用。
研究设计与样本
- 前瞻性队列研究,纳入连续住院的肝硬化合并AKI患者,共139例患者的202次AKI发作。
- EASL管理算法包括识别和处理诱因、对AKI≥1B期患者予2天白蛋白输注、对HRS-AKI患者予特利加压素治疗。
- 主要结局为治疗应答(包括完全应答和部分应答),次要结局为生存及特利加压素相关不良事件。
主要发现
- 总体治疗应答率为80%,仅8%需要肾脏替代治疗。
- 白蛋白输注在三分之一的发作中取得应答。
- 对白蛋白无应答者中多数(74%)不符合HRS-AKI诊断标准,急性肾小管坏死为最常见表型。
- 不符合HRS-AKI诊断标准者的应答率为70%;符合HRS-AKI诊断标准者仅30例,对特利加压素应答率为61%。
- uNGAL可区分急性肾小管坏死与其他表型(AUROC 0.78),但不能预测HRS-AKI对治疗的应答;90天无移植生存与MELD-Na、急性肾小管坏死、HRS-AKI及uNGAL呈负相关;3例使用特利加压素者发生肺水肿。
关键数值与推荐
- AKI总体治疗应答率80%,肾脏替代治疗需求8%。
- 白蛋白输注应答率约三分之一。
- 不符合HRS-AKI诊断标准者应答率70%,符合HRS-AKI诊断标准者对特利加压素应答率61%。
- AKI诊断至特利加压素启动的中位时间仅2.5天。
- uNGAL区分急性肾小管坏死与其他表型的AUROC为0.78。
临床怎么用
- 作者认为这些发现支持该EASL AKI算法在临床实践中使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The management of acute kidney injury (AKI) in cirrhosis is challenging. The EASL guidelines proposed an algorithm for the management of AKI, but this has never been validated. We aimed to prospectively evaluate this algorithm in clinical practice. METHODS: We performed a prospective cohort study in consecutive hospitalized patients with cirrhosis and AKI. The EASL management algorithm includes identification/treatment of precipitating factors, 2-day albumin infusion in patients with AKI ≥stage 1B, and treatment with terlipressin in patients with hepatorenal syndrome (HRS-AKI). The primary outcome was treatment response, which included both full and partial response. Secondary outcomes were survival and adverse events associated with terlipressin therapy. RESULTS: A total of 202 AKI episodes in 139 patients were included. Overall treatment response was 80%, while renal replacement therapy was required in only 8%. Response to albumin infusion was achieved in one-third of episodes. Of patients not responding to albumin, most (74%) did not meet the diagnostic criteria of HRS-AKI, with acute tubular necrosis (ATN) being the most common phenotype. The response rate in patients not meeting the criteria for HRS-AKI was 70%. Only 30 patients met the diagnostic criteria for HRS-AKI, and their response rate to terlipressin was 61%. Median time from AKI diagnosis to terlipressin initiation was only 2.5 days. While uNGAL (urinary neutrophil gelatinase-associated lipocalin) could differentiate ATN from other phenotypes (AUROC 0.78), it did not predict response to therapy in HRS-AKI. Ninety-day transplant-free survival was negatively associated with MELD-Na, ATN and HRS-AKI as well as uNGAL. Three patients treated with terlipressin developed pulmonary edema. CONCLUSIONS: The application of the EASL AKI algorithm is associated with very good response rates and does not significantly delay initiation of terlipressin therapy. IMPACT AND IMPLICATIONS: The occurrence of acute kidney injury (AKI) in patients with cirrhosis is associated with poor short-term mortality. Improving its rapid identification and prompt management was the focus of the recently proposed EASL AKI algorithm. This is the first prospective study demonstrating that high AKI response rates are achieved with the use of this algorithm, which includes identification of AKI, treatment of precipitating factors, a 2-day albumin challenge in patients with AKI ≥1B, and supportive therapy in patients with persistent AKI not meeting HRS-AKI criteria or terlipressin with albumin in those with HRS-AKI. These findings support the use of this algorithm in clinical practice.
引用
- Ma AT, Solé C, Juanola A, et al. Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis. J Hepatol. 2024. PMID: 38479614. doi:10.1016/j.jhep.2024.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。